Azithromycin Dose and PPROM Treatment: a Pilot Randomized Controlled Trial

NCT ID: NCT04294069

Last Updated: 2023-07-27

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

6 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-09-14

Study Completion Date

2021-04-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a pilot randomized controlled trial to assess the pharmacokinetics and pharmacodynamics of azithromycin in pregnant singletons admitted with preterm premature rupture of membranes (PPROM) at 24 0/7- 33 0/7. Participants will be randomized 1:1 to either 1000mg azithromycin orally once or 500mg azithromycin orally daily for seven days in addition to standard care.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a pilot randomized controlled trial to assess the pharmacokinetics and pharmacodynamics of azithromycin in pregnant singletons admitted with preterm premature rupture of membranes (PPROM) at 24 0/7- 33 0/7. Participants will be randomized 1:1 to either 1000mg azithromycin orally once or 500mg azithromycin orally daily for seven days in addition to standard care. During the course of eight days participants will have serial collection of amniotic fluid, maternal serum; and at delivery, of placenta, membrane, and cord blood. After delivery, neonatal respiratory samples will be collected as well.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Preterm Premature Rupture of Membrane

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Randomized controlled trial
Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Azithromycin 500mg

500mg azithromycin PO daily for seven days

Group Type ACTIVE_COMPARATOR

Azithromycin 500 mg

Intervention Type DRUG

500mg azithromycin PO for seven days starting on admission

Azithromycin 1000mg

1000mg azithromycin PO once at admission

Group Type ACTIVE_COMPARATOR

Azithromycin Oral Product

Intervention Type DRUG

1000mg azithromycin PO once at admission

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Azithromycin 500 mg

500mg azithromycin PO for seven days starting on admission

Intervention Type DRUG

Azithromycin Oral Product

1000mg azithromycin PO once at admission

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Singleton gestation 24 0/7 -33 0/7 weeks'
* Diagnosed with preterm premature rupture of membranes:

* History consistent with ruptured membranes (ie leaking, gush of fluid)
* Sterile speculum exam with pooling
* Fluid positive for ferning and/or nitrazine
* With or without confirmatory test such as Amnisure

Exclusion Criteria

* • Contraindication to azithromycin

* Active labor, abruption, chorioamnionitis at enrollment
* Other contraindication to expectant management of PPROM at enrollment
Minimum Eligible Age

14 Years

Maximum Eligible Age

65 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Christiana Care Health Services

OTHER

Sponsor Role collaborator

Thomas Jefferson University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Rupsa C Boelig, MD

Role: PRINCIPAL_INVESTIGATOR

Thomas Jefferson University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Thomas Jefferson University Hospital

Philadelphia, Pennsylvania, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

20G.119

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Vitality in Infants Via Azithromycin for Neonates Trial
NCT05763693 NOT_YET_RECRUITING PHASE4